**BACKGROUND**

SOR-C13 is a first-in-man, selective, peptide inhibitor of Transient Receptor Potential Vanilloid 6 (TRPV6) calciunon channel. TRPV6 is highly elevated in carcinomas including prostate, breast, lung and ovary and is correlated with poor outcomes. TRPV6-mediated Ca++ entry is responsible for maintaining a high proliferation rate, increasing cell survival and apoptosis resistance through calcineurin/NFAT pathways (1, 2, 3).

**Methods**

Primary: Patient Safety

Methods, Particular interest: SOR-C13 was safe and well tolerated in subjects with advanced solid tumors of epithelial origin and demonstrates potential activity in these subjects. Further development is warranted.

**REFERENCES**


**CONCLUSIONS**

SOR-C13 was safe and well tolerated in subjects with advanced solid tumors of epithelial origin and demonstrates potential activity in these subjects. Further development is warranted.

**ACKNOWLEDGEMENTS**

We gratefully acknowledge the patients and their families for their participation in this study. We also acknowledge the contributions of C. G. Hille, Juravinski Cancer Centre, Hamilton ON. Canada. We acknowledge S. Poer for her work in the lab and clinical samples.

**SPONSOR**

Soricimed Biopharma Inc. www.soricimed.com